Market Overview

Cook Medical Introduces a New Length of Zilver® PTX®


Cook Medical has introduced the 140 mm-length Zilver® PTX® Drug-Eluting
Peripheral Stent in both 6 and 7 mm diameters in the U.S. The longer
length comes after an expanded indication approval by FDA to treat total
lesion lengths up to 300 mm per patient. In addition, the product also
received an extended shelf life of two years by the FDA.

The 140-mm length stents will enable physicians when applicable to treat
lesions up to 270-mm with only two stents. In addition to this benefit,
Zilver PTX has been shown to cut reinterventions by nearly half in 5
years, compared to a combination of bare-metal Zilver stents and PTA.1

"We're happy to continually broaden the Zilver PTX product offering,
giving physicians more options when treating superficial femoral artery
disease based on the individual patient need," said Mark Breedlove, vice
president of Cook Medical's vascular division.

Zilver PTX2 is the world's first drug-eluting stent for
treating peripheral arterial disease (PAD) in the superficial femoral
artery (SFA) and is the only drug-eluting SFA stent with five-year
published data.

About Cook Medical

Since 1963 Cook Medical has worked closely with physicians to develop
technologies that eliminate the need for open surgery. Today we are
combining medical devices, biologic materials and cellular therapies to
help the world's healthcare systems deliver better outcomes more
efficiently. We have always remained family owned so that we have the
freedom to focus on what we care about: patients, our employees and our
communities. Find out more at, and
for the latest news, follow us on Twitter,
Facebook and LinkedIn

1 Dake MD, Ansel GM, Jaff MR, et al. Durable clinical
effectiveness with paclitaxel-eluting stents in the femoropopliteal
artery: 5-year results of the Zilver PTX

2 Caution: U.S. federal law restricts this device to sale by
or on the order of a physician (or properly licensed practitioner). Use
of this drug-eluting peripheral stent carries the risks associated with
peripheral artery stenting, including vascular complications and/or
bleeding events. Refer to the Instructions for Use (IFU) for full
prescribing information including information on potential adverse
events, contraindications, warnings, precautions, and summary of
clinical data.

View Comments and Join the Discussion!